PharmaTimes: News RSS
Vertex offers ‘portfolio approach’ to secure access to CF meds
Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients to its current and future portfolio of cystic fibrosis (CF) medicines.
NICE gives three nods in thyroid cancer
Ipsen’s Cometriq and Bayer’s Nexavar to come off the Cancer Drugs Fund and into routine NHS use
Janssen’s psoriasis biologic Tremfya shows long-term effect
Top-line trial data unveiled by Janssen at the 2018 American Academy of Dermatology (AAD) Annual Meeting over the weekend indicate that the benefit of Tremfya in patients with severe plaque psoriasis is maintained in the long-term.
Manchester CRN gets ‘Premier Site’ status from Sanofi
French drugmaker Sanofi has named NIHR Clinical Research Network Greater Manchester as its first UK Premier Site, marking a “landmark” clinical research partnership that will help accelerate R&D to address the medical need of patients.
US clears AZ’ Imfinzi for lung cancer
US regulators have expanded the scope of AstraZeneca/MedImmune’s immunotherapy Imfinzi to include patients with a certain form of lung cancer.
Roche to acquire Flatiron Health
Will use cancer patient's data for R&D for personalised medicines
Merck and Pfizer’s immunotherapy fails in late-stage trial
Bavencio (avelumab) has failed to meet its primary endpoint in a lung cancer trial
Tetraphase stock plummets on antibiotic failure
Tetraphase Pharmaceuticals saw its stock plummet after revealing that a Phase III study of its experimental antibiotic eravacycline missed key targets in a late stage trial.
Shire’s SHP647 bags another orphan badge
US regulators have awarded orphan drug status to Shire's investigational therapy, SHP647, for the treatment of paediatric patients with moderately to severely active Crohn's disease.
NHS rolls out KardiaMobile to accelerate detection of arrhythmia
The NHS has launched a new device in England designed to accelerate the diagnosis of atrial fibrillation (AF), the most common arrhythmia and a contributing factor of up to one in five strokes in the UK.
BMS, Nektar to jointly develop, commercialise immunotherapy combo
Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter’s lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact.
Green light for Celltrion’s Herceptin biosimilar
The European Commission has approved Celltrion Healthcare’s Herzuma, a biosimilar of Roche/Genentech’s blockbuster Herceptin.
Study reveals stark North-South divide in opioid prescriptions
Researchers are calling for a national database of high opioid users after finding that the number prescriptions and related deaths in England is on the rise, especially in poorer communities.
Lilly’s Taltz hits goals in PhIII ankylosing spondylitis trial
Regulatory submissions for Lilly’s Taltz in ankylosing spondylitis (AS) are on the cards for later this year after the drug hit primary and secondary targets in a late-stage trial.
Bicycle, CR UK launch first trial of a bicyclic peptide
Bicycle Therapeutics and Cancer Research UK have initiated the first clinical study to assess a bicyclic peptide, evaluating its potential in patients with advanced solid tumours.
Feed Fetched by RSS Dog.